Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for NeuroMetrix, Inc. (NURO : NSDQ)
 
 • Company Description   
Neurometrix is a medical device company establishing a new standard of care through the design, development and sale of proprietary products used to diagnose neuropathies. Neuropathies are diseases of the peripheral nerves and parts of the spine that frequently are caused by or associated with diabetes, low back pain and carpal tunnel syndrome, as well as other clinical disorders.

Number of Employees: 23

 
 • Price / Volume Information   
Yesterday's Closing Price: $3.38 Daily Weekly Monthly
20 Day Moving Average: 73,905 shares
Shares Outstanding: 7.13 (millions)
Market Capitalization: $24.10 (millions)
Beta: 2.85
52 Week High: $38.75
52 Week Low: $2.70
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -19.33% -11.97%
12 Week -21.03% -16.86%
Year To Date -32.67% -21.52%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
4B GILL STREET WOBURN
-
MASSACHUSETTS,MA 01801
USA
ph: 781-890-9989
fax: 302-636-5454
neurometrix.ir@neurometrix.com http://www.neurometrix.com
 
 • General Corporate Information   
Officers
Shai N. Gozani - Chief Executive Officer; Chairman and President
Thomas T. Higgins - Senior Vice President; Chief Financial Officer and
David E. Goodman - Director
Nancy E. Katz - Director
David Van Avermaete - Director

Peer Information
NeuroMetrix, Inc. (BJCT)
NeuroMetrix, Inc. (CADMQ)
NeuroMetrix, Inc. (APNO)
NeuroMetrix, Inc. (UPDC)
NeuroMetrix, Inc. (IMTIQ)
NeuroMetrix, Inc. (CYGN)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED PRODUCTS
Sector: Medical
CUSIP: 641255807
SIC: 3841
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 07/28/22
Share - Related Items
Shares Outstanding: 7.13
Most Recent Split Date: 11.00 (0.10:1)
Beta: 2.85
Market Capitalization: $24.10 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 07/28/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.99
Price/Cash Flow: -
Price / Sales: 2.87
EPS Growth
vs. Year Ago Period: -600.00%
vs. Previous Quarter: 6.67%
Sales Growth
vs. Year Ago Period: 6.77%
vs. Previous Quarter: 26.48%
ROE
03/31/22 - -15.80
12/31/21 - -14.83
09/30/21 - -14.73
ROA
03/31/22 - -14.43
12/31/21 - -13.10
09/30/21 - -12.16
Current Ratio
03/31/22 - 14.82
12/31/21 - 17.71
09/30/21 - 14.72
Quick Ratio
03/31/22 - 14.40
12/31/21 - 17.19
09/30/21 - 14.15
Operating Margin
03/31/22 - -37.87
12/31/21 - -27.65
09/30/21 - -19.47
Net Margin
03/31/22 - -37.87
12/31/21 - -27.65
09/30/21 - -19.47
Pre-Tax Margin
03/31/22 - -37.86
12/31/21 - -27.64
09/30/21 - -19.47
Book Value
03/31/22 - 3.40
12/31/21 - 3.48
09/30/21 - 3.63
Inventory Turnover
03/31/22 - 2.63
12/31/21 - 2.51
09/30/21 - 2.20
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©